|Place of Origin:||China|
|Brand Name:||Senwayer Brand|
|Certification:||ISO, 9001, USP|
|Minimum Order Quantity:||10grams|
|Price:||Discount is possible if your order is big enough|
|Packaging Details:||10g, 20g, 50g , 100g, 500g. 1kg, 10kg|
|Delivery Time:||within 2 working days|
|Payment Terms:||T/T in advance, Money Gram, Western Union, Bank Transfer.|
|CAS:||136236-51-6||Alias:||Rasagiline, Rasagiline -13C3|
|Apparence:||Almost White Crystalline Powder||Purity:||99%|
|Stock:||Enough Stock||Grade:||Pharma Grade|
top weight loss supplements,
weight loss steroids
Safe Medical Rasagiline Prevent Obesity Raw Material Drug CAS 136236-51-6 Powder
Product Name: Rasagiline
Synonyms: (R)-2,3-DIHYDRO-N-2-PROPYNYL-1H-INDEN-1-AMINE;Rasagiline -13C3;Rasagiline;(R)-N-2-Propynyl-1-indanamine;1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R);1-Indanamine, N-2-propynyl-, (R)-;Unii-003N66ts6t;(R)-N-(2-Propynyl)-2,3-dihydroinden-1-aMine
Product Categories: ZELNORM
MOQ: 10 Gram Available
Packaging Detail:25Kg / Fiber Drum
Payment Terms: T/T, MoneyGram, Western Union and Bitcoin
Delivery Method: HKEMS, DHL, TNT, UPS, FEDEX, EMS, China Air Post etc.
Clearance Rate: 100% Custom Pass, Disguise Package and Safe
Leading Time: at the very day after payment
Delivery Time: 5-14 Working Days, Tracking Number Available
Origin Place: Hubei Province, China
Production Capacity: 500Kg/Month
Description of Rasagiline :
Rasagiline is used alone or in combination with another medication to treat the symptoms of Parkinson's disease (a slowly progressing disease of the nervous system causing a fixed face without expression, tremor at rest, slowing of movements, walking with shuffling steps, stooped posture and muscle weakness). Rasagiline is in a class of medications called monoamine oxidase (MAO) type B inhibitors. It works by increasing the amounts of certain natural substances in the brain.
How should this medicine be used?
Rasagiline comes as a tablet to take by mouth. It is usually taken once a day with or without food. Take rasagiline at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take rasagiline exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
Your doctor may start you on a low dose of rasagiline and may increase your dose based upon your body's response to this medication.
Do not stop taking rasagiline without talking to your doctor. Your doctor will probably decrease your dose gradually. If you suddenly stop taking rasagiline, you may experience withdrawal symptoms such as a fever; muscle stiffness; unsteadiness, wobbliness, or lack of coordination; or changes in consciousness. Tell your doctor if you experience any of these symptoms when your dose of rasagiline is decreased.
General Dosing Recommendations
When AZILECT is prescribed as monotherapy or as adjunct therapy in patients not taking levodopa, patients may start AZILECT at the recommended dose of 1 mg administered orally once daily.
In patients taking levodopa, with or without other PD drugs (e.g., dopamineagonist, amantadine, anticholinergics), the recommended initial dose of AZILECT is 0.5 mg once daily. If the patient tolerates the daily 0.5 mg dose, but a sufficient clinical response is not achieved, the dose may be increased to 1 mg once daily. When AZILECT is used in combination with levodopa, a reduction of the levodopa dose may be considered, based upon individual response.
The recommended doses of AZILECT should not be exceeded because of risk of hypertension [see WARNINGS AND PRECAUTIONS].
Patients Taking Ciprofloxacin Or Other CYP1A2 Inhibitors
Patients taking concomitant ciprofloxacin or other CYP1A2 inhibitors should not exceed a dose of AZILECT 0.5 mg once daily [see WARNINGS ANDPRECAUTIONS, DRUG INTERACTIONS, and CLINICAL PHARMACOLOGY].
Patients With Hepatic Impairment
Patients with mild hepatic impairment should not exceed a dose of AZILECT 0.5 mg once daily. AZILECT should not be used in patients with moderate or severe hepatic impairment [see WARNINGS AND PRECAUTIONS, Use In Specific Populations, and CLINICAL PHARMACOLOGY].